Fibrinogen splice variation and cross-linking: Effects on fibrin structure/function and role of fibrinogen γ′ as thrombomobulin II

Matrix Biology

Volumn 60-61, Issue , 2017, Pages 8-15

  Duval, Cédric ^a   Ariëns, Robert A S ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Cross linking; Fibrin clot; Fibrinogen; Splice variant

Indexed keywords

ANTIFIBRINOLYTIC AGENT; BLOOD CLOTTING FACTOR 13; FIBRIN; FIBRIN ALPHA; FIBRIN GAMMA; FIBRINOGEN; FIBRINOGEN ALPHA EC; FIBRINOGEN GAMMA'; THROMBOMODULIN; THROMBOMODULIN II; UNCLASSIFIED DRUG; CROSS LINKING REAGENT; FIBRINOGEN VARIANT; ISOPROTEIN; THBD PROTEIN, HUMAN;

BLEEDING; BLOOD CLOT; CHEMICAL BOND; FIBRIN CLOT; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CROSS LINKING; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN SPLICING; PROTEIN STRUCTURE; REVIEW; THROMBOSIS; TISSUE REPAIR; ALTERNATIVE RNA SPLICING; BLOOD CLOTTING; CHEMISTRY; GENE EXPRESSION; GENETIC POLYMORPHISM; GENETICS; GLYCOSYLATION; METABOLISM; PHYSIOLOGY; PROTEIN PROCESSING; WOUND HEALING;

ALTERNATIVE SPLICING; BLOOD COAGULATION; CROSS-LINKING REAGENTS; FACTOR XIII; FIBRIN; FIBRINOGENS, ABNORMAL; GENE EXPRESSION; GLYCOSYLATION; HUMANS; POLYMORPHISM, GENETIC; PROTEIN ISOFORMS; PROTEIN PROCESSING, POST-TRANSLATIONAL; THROMBOMODULIN; WOUND HEALING;

EID: 85006766627     PISSN: 0945053X     EISSN: 15691802     Source Type: Journal    
DOI: 10.1016/j.matbio.2016.09.010     Document Type: Review

References (51)

1. Henschen, A.H., Human fibrinogen—structural variants and functional sites. Thromb. Haemost. 70 (1993), 42–47.
2. Undas, A., Ariens, R.A., Fibrin clot structure and function: a role in the pathophysiology of arterial and venous thromboembolic diseases. Arterioscler. Thromb. Vasc. Biol. 31 (2011), e88–e99.
3. Litvinov, R.I., Weisel, J.W., Fibrin mechanical properties and their structural origins. Matrix Biol., 2016.
4. Grieninger, G., Contribution of the alpha EC domain to the structure and function of fibrinogen-420. Ann. N. Y. Acad. Sci. 936 (2001), 44–64.
5. Fu, Y., Cao, Y., Hertzberg, K.M., Grieninger, G., Fibrinogen alpha genes: conservation of bipartite transcripts and carboxy-terminal-extended alpha subunits in vertebrates. Genomics 30 (1995), 71–76.
6. Spraggon, G., Applegate, D., Everse, S.J., Zhang, J.Z., Veerapandian, L., Redman, C., Doolittle, R.F., Grieninger, G., Crystal structure of a recombinant alphaEC domain from human fibrinogen-420. Proc. Natl. Acad. Sci. U. S. A. 95 (1998), 9099–9104.
7. Applegate, D., Steben, L.S., Hertzberg, K.M., Grieninger, G., The alpha(E)C domain of human fibrinogen-420 is a stable and early plasmin cleavage product. Blood 95 (2000), 2297–2303.
8. Lishko, V.K., Yakubenko, V.P., Hertzberg, K.M., Grieninger, G., Ugarova, T.P., The alternatively spliced alpha(E)C domain of human fibrinogen-420 is a novel ligand for leukocyte integrins alpha(M)beta(2) and alpha(X)beta(2). Blood 98 (2001), 2448–2455.
9. Mosesson, M.W., DiOrio, J.P., Hernandez, I., Hainfeld, J.F., Wall, J.S., Grieninger, G., The ultrastructure of fibrinogen-420 and the fibrin-420 clot. Biophys. Chem. 112 (2004), 209–214.
10. Macrae, F.L., Domingues, M.M., Casini, A., Ariens, R.A., The (patho)physiology of fibrinogen gamma. Semin. Thromb. Hemost., 2016.
11. Pieters, M., Kotze, R.C., Jerling, J.C., Kruger, A., Ariens, R.A., Evidence that fibrinogen gamma’ regulates plasma clot structure and lysis and relationship to cardiovascular risk factors in black Africans. Blood 121 (2013), 3254–3260.
12. Allan, P., Uitte de Willige, S., Abou-Saleh, R.H., Connell, S.D., Ariens, R.A., Evidence that fibrinogen gamma’ directly interferes with protofibril growth: implications for fibrin structure and clot stiffness. J. Thromb. Haemost. 10 (2012), 1072–1080.
13. Gersh, K.C., Nagaswami, C., Weisel, J.W., Lord, S.T., The presence of gamma’ chain impairs fibrin polymerization. Thromb. Res. 124 (2009), 356–363.
14. Domingues, M.M., Macrae, F.L., Duval, C., McPherson, H.R., Bridge, K.I., Ajjan, R.A., Ridger, V.C., Connell, S.D., Philippou, H., Ariens, R.A., Thrombin and fibrinogen gamma’ impact clot structure by marked effects on intrafibrillar structure and protofibril packing. Blood 127 (2016), 487–495.
15. Kim, P.Y., Vu, T.T., Leslie, B.A., Stafford, A.R., Fredenburgh, J.C., Weitz, J.I., Reduced plasminogen binding and delayed activation render gamma'-fibrin more resistant to lysis than gammaA-fibrin. J. Biol. Chem. 289 (2014), 27494–27503.
16. Ariens, R.A., Fibrin(ogen) and thrombotic disease. J. Thromb. Haemost. 11:Suppl. 1 (2013), 294–305.
17. Pineda, A.O., Chen, Z.W., Marino, F., Mathews, F.S., Mosesson, M.W., Di Cera, E., Crystal structure of thrombin in complex with fibrinogen gamma’ peptide. Biophys. Chem. 125 (2007), 556–559.
18. Hemker, H.C., Giesen, P.L., Ramjee, M., Wagenvoord, R., Beguin, S., The thrombogram: monitoring thrombin generation in platelet-rich plasma. Thromb. Haemost. 83 (2000), 589–591.
19. Mosesson, M.W., Update on antithrombin I (fibrin). Thromb. Haemost. 98 (2007), 105–108.
20. Kremers, R.M., Wagenvoord, R.J., Hemker, H.C., The effect of fibrin(ogen) on thrombin generation and decay. Thromb. Haemost. 112 (2014), 486–494.
21. Lovely, R.S., Boshkov, L.K., Marzec, U.M., Hanson, S.R., Farrell, D.H., Fibrinogen gamma’ chain carboxy terminal peptide selectively inhibits the intrinsic coagulation pathway. Br. J. Haematol. 139 (2007), 494–503.
22. Omarova, F., Uitte De Willige, S., Ariens, R.A., Rosing, J., Bertina, R.M., Castoldi, E., Inhibition of thrombin-mediated factor V activation contributes to the anticoagulant activity of fibrinogen gamma. J. Thromb. Haemost. 11 (2013), 1669–1678.
23. Omarova, F., Uitte de Willige, S., Simioni, P., Ariens, R.A., Bertina, R.M., Rosing, J., Castoldi, E., Fibrinogen gamma’ increases the sensitivity to activated protein C in normal and factor V Leiden plasma. Blood 124 (2014), 1531–1538.
24. Cooper, A.V., Standeven, K.F., Ariens, R.A., Fibrinogen gamma-chain splice variant gamma’ alters fibrin formation and structure. Blood 102 (2003), 535–540.
25. Siebenlist, K.R., Meh, D.A., Mosesson, M.W., Plasma factor XIII binds specifically to fibrinogen molecules containing gamma chains. Biochemistry 35 (1996), 10448–10453.
26. Moaddel, M., Farrell, D.H., Daugherty, M.A., Fried, M.G., Interactions of human fibrinogens with factor XIII: roles of calcium and the gamma’ peptide. Biochemistry 39 (2000), 6698–6705.
27. Moaddel, M., Falls, L.A., Farrell, D.H., The role of gamma a/gamma ' fibrinogen in plasma factor XIII activation. J. Biol. Chem. 275 (2000), 32135–32140.
28. Siebenlist, K.R., Meh, D.A., Mosesson, M.W., Protransglutaminase (factor XIII) mediated crosslinking of fibrinogen and fibrin. Thromb. Haemost. 86 (2001), 1221–1228.
29. Duval, C., Philippou, H., Ariens, R.A., Factor XIII. Marder, V.J., Aird, W.C., Bennett, J.S., Schulman, S., White, G.C., (eds.) Hemostasis and Thrombosis: Basic Principles and Clinical Practice, 2012, Lippincott Williams & Wilkins, Philadelphia, 272–285.
30. McKee, P.A., Mattock, P., Hill, R.L., Subunit structure of human fibrinogen, soluble fibrin, and cross-linked insoluble fibrin. Proc. Natl. Acad. Sci. U. S. A. 66 (1970), 738–744.
31. Duval, C., Ali, M., Chaudhry, W.W., Ridger, V.C., Ariens, R.A., Philippou, H., Factor XIII A-subunit V34L variant affects thrombus cross-linking in a murine model of thrombosis. Arterioscler. Thromb. Vasc. Biol. 36 (2016), 308–316.
32. Dorgalaleh, A., Rashidpanah, J., Blood coagulation factor XIII and factor XIII deficiency. Blood Rev., 2016.
33. Gorkun, O.V., Henschen-Edman, A.H., Ping, L.F., Lord, S.T., Analysis of A alpha 251 fibrinogen: the alpha C domain has a role in polymerization, albeit more subtle than anticipated from the analogous proteolytic fragment X. Biochemistry 37 (1998), 15434–15441.
34. Collet, J.P., Moen, J.L., Veklich, Y.I., Gorkun, O.V., Lord, S.T., Montalescot, G., Weisel, J.W., The alphaC domains of fibrinogen affect the structure of the fibrin clot, its physical properties, and its susceptibility to fibrinolysis. Blood 106 (2005), 3824–3830.
35. Standeven, K.F., Carter, A.M., Grant, P.J., Weisel, J.W., Chernysh, I., Masova, L., Lord, S.T., Ariens, R.A., Functional analysis of fibrin {gamma}-chain cross-linking by activated factor XIII: determination of a cross-linking pattern that maximizes clot stiffness. Blood 110 (2007), 902–907.
36. Duval, C., Allan, P., Connell, S.D., Ridger, V.C., Philippou, H., Ariens, R.A., Roles of fibrin alpha- and gamma-chain specific cross-linking by FXIIIa in fibrin structure and function. Thromb. Haemost. 111 (2014), 842–850.
37. Helms, C.C., Ariens, R.A., Uitte de Willige, S., Standeven, K.F., Guthold, M., Alpha-alpha cross-links increase fibrin fiber elasticity and stiffness. Biophys. J. 102 (2012), 168–175.
38. Kurniawan, N.A., Grimbergen, J., Koopman, J., Koenderink, G.H., Factor XIII stiffens fibrin clots by causing fiber compaction. J. Thromb. Haemost. 12 (2014), 1687–1696.
39. Homer, V.M., Mullin, J.L., Brennan, S.O., Barr, A., George, P.M., Novel Aalpha chain truncation (fibrinogen Perth) resulting in low expression and impaired fibrinogen polymerization. J. Thromb. Haemost. 1 (2003), 1245–1250.
40. Collet, J.P., Woodhead, J.L., Soria, J., Soria, C., Mirshahi, M., Caen, J.P., Weisel, J.W., Fibrinogen Dusart: electron microscopy of molecules, fibers and clots, and viscoelastic properties of clots. Biophys. J. 70 (1996), 500–510.
41. Fuchs, G., Egbring, R., Havemann, K., Fibrinogen Marburg a new genetic variant of fibrinogen. Blut 34 (1977), 107–118.
42. Byrnes, J.R., Duval, C., Wang, Y., Hansen, C.E., Ahn, B., Mooberry, M.J., Clark, M.A., Johnsen, J.M., Lord, S.T., Lam, W.A., Meijers, J.C., Ni, H., Ariens, R.A., Wolberg, A.S., Factor XIIIa-dependent retention of red blood cells in clots is mediated by fibrin alpha-chain crosslinking. Blood 126 (2015), 1940–1948.
43. Carlisle, C.R., Sparks, E.A., Der Loughian, C., Guthold, M., Strength and failure of fibrin fiber branchpoints. J. Thromb. Haemost. 8 (2010), 1135–1138.
44. Fraser, S.R., Booth, N.A., Mutch, N.J., The antifibrinolytic function of factor XIII is exclusively expressed through alpha(2)-antiplasmin cross-linking. Blood 117 (2011), 6371–6374.
45. Rijken, D.C., Abdul, S., Malfliet, J.J., Leebeek, F.W., Uitte de Willige, S., Compaction of fibrin clots reveals the antifibrinolytic effect of factor XIII. J. Thromb. Haemost., 2016.
46. Mutch, N.J., Moore, N.R., Wang, E., Booth, N.A., TAFI is cross-linked by its activation peptide to sites on fibrin(ogen) distinct from other inhibitors of fibrinolysis. J. Thromb. Haemost., 1, 2003, OC064.
47. Richardson, V.R., Cordell, P., Standeven, K.F., Carter, A.M., Substrates of factor XIII-A: roles in thrombosis and wound healing. Clin. Sci. (Lond.) 124 (2013), 123–137.
48. Ramanathan, A., Karuri, N., Fibronectin alters the rate of formation and structure of the fibrin matrix. Biochem. Biophys. Res. Commun. 443 (2014), 395–399.
49. Collet, J.P., Park, D., Lesty, C., Soria, J., Soria, C., Montalescot, G., Weisel, J.W., Influence of fibrin network conformation and fibrin fiber diameter on fibrinolysis speed: dynamic and structural approaches by confocal microscopy. Arterioscler. Thromb. Vasc. Biol. 20 (2000), 1354–1361.
50. Bale, M.D., Mosher, D.F., Thrombospondin is a substrate for blood coagulation factor XIIIa. Biochemistry 25 (1986), 5667–5673.
51. Bale, M.D., Mosher, D.F., Effects of thrombospondin on fibrin polymerization and structure. J. Biol. Chem. 261 (1986), 862–868.